Ascentage Pharma (AAPG) director corrects option and RSU grant details

Rhea-AI Filing Summary

ASCENTAGE PHARMA GROUP INTERNATIONAL director Marina Bozilenko filed an amended Form 3 to update her equity awards. She reports stock options over 17,965 Ordinary Shares at an exercise price of 8.1400 per share, expiring on November 26, 2035, vesting in twelve equal monthly tranches starting November 26, 2025.

She also holds restricted share units covering 27,965 Ordinary Shares, which vest in four equal increments on each of November 26, 2026, 2027, 2028 and 2029. The amendment notes that the number and/or vesting of the share options were inadvertently incorrectly reported in the original submission and are now corrected.

Insider Trade Summary

2 transactions reported

Mixed 2 txns

Insider Bozilenko Marina

Role Director

Type	Security	Shares	Price	Value
holding	Options	--	--	--
holding	Restricted share units	--	--	--

Holdings After Transaction: Options — 17,965 shares (Direct); Restricted share units — 27,965 shares (Direct)

Footnotes (1)

1. The stock options vest in twelve (12) tranches equally on the 26th of the month starting November 26, 2025. The exercise price for the stock options is in HKD, and the exercise price included in the table represents conversion to USD based on the exchange rate on the date of grant. Each restricted stock unit (RSUs) represents a contingent right to receive one Ordinary Share of the Issuer upon vesting. The RSUs vest in four equal increments on each of 11/26/2026, 2027, 2028 and 2029. The number of Share Options and/or their vesting were inadvertently incorrectly reported in the original submission.

Understanding Insider Trading Forms →

SEC Form 3

FORM 3

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

INITIAL STATEMENT OF BENEFICIAL OWNERSHIP OF SECURITIES

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0104
Estimated average burden
hours per response:			0.5

1. Name and Address of Reporting Person^*

Bozilenko Marina

(Last) (First) (Middle)

700 KING FARM BLVD

STE 510

(Street)

ROCKVILLE MARYLAND 20850

(City) (State) (Zip)

UNITED STATES

(Country)

2. Date of Event Requiring Statement (Month/Day/Year)
03/18/2026

3. Issuer Name and Ticker or Trading Symbol
ASCENTAGE PHARMA GROUP INTERNATIONAL [ AAPG ]

3a. Foreign Trading Symbol

5. If Amendment, Date of Original Filed (Month/Day/Year)
03/19/2026

4. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

X	Director		10% Owner
	Officer (give title below)		Other (specify below)

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

Table I - Non-Derivative Securities Beneficially Owned
1. Title of Security (Instr. 4)	2. Amount of Securities Beneficially Owned (Instr. 4)	3. Ownership Form: Direct (D) or Indirect (I) (Instr. 5)	4. Nature of Indirect Beneficial Ownership (Instr. 5)

Table II - Derivative Securities Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 4)	2. Date Exercisable and Expiration Date (Month/Day/Year)		3. Title and Amount of Securities Underlying Derivative Security (Instr. 4)		4. Conversion or Exercise Price of Derivative Security	5. Ownership Form: Direct (D) or Indirect (I) (Instr. 5)	6. Nature of Indirect Beneficial Ownership (Instr. 5)
	Date Exercisable	Expiration Date	Title	Amount or Number of Shares
Options	(1)	11/26/2035	Ordinary Shares	17,965(4)	$8.14(2)	D
Restricted share units	(3)	(3)	Ordinary Shares	27,965(4)	$0	D

Explanation of Responses:

1. The stock options vest in twelve (12) tranches equally on the 26th of the month starting November 26, 2025.

2. The exercise price for the stock options is in HKD, and the exercise price included in the table represents conversion to USD based on the exchange rate on the date of grant.

3. Each restricted stock unit (RSUs) represents a contingent right to receive one Ordinary Share of the Issuer upon vesting. The RSUs vest in four equal increments on each of 11/26/2026, 2027, 2028 and 2029.

4. The number of Share Options and/or their vesting were inadvertently incorrectly reported in the original submission.

Remarks:

This form is filed using a special power of attorney.

	Thomas J. Knapp	03/23/2026
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 5 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.
* Form 3: SEC 1473 (03-26)

FAQ

What did Ascentage Pharma (AAPG) director Marina Bozilenko report in this amended Form 3?

She updated her disclosed equity awards, confirming holdings of stock options and restricted share units in Ascentage Pharma. The amendment corrects previously misreported option numbers and vesting terms, providing a more accurate picture of her compensation-related interests in the company.

How many Ascentage Pharma (AAPG) shares are covered by Marina Bozilenko’s stock options?

Her options relate to 17,965 underlying Ordinary Shares of Ascentage Pharma. These options carry an exercise price of 8.1400 per share and expire on November 26, 2035, with vesting in twelve equal monthly tranches beginning on November 26, 2025.

What are the vesting terms of Marina Bozilenko’s restricted share units in Ascentage Pharma (AAPG)?

Her restricted share units cover 27,965 Ordinary Shares and vest in four equal annual increments. The vesting dates are November 26, 2026, November 26, 2027, November 26, 2028 and November 26, 2029, each RSU delivering one Ordinary Share upon vesting.

Why was Marina Bozilenko’s Form 3 for Ascentage Pharma (AAPG) amended?

The amendment states that the number of share options and/or their vesting were inadvertently incorrectly reported previously. This Form 3/A corrects those details so the reported derivative holdings and vesting schedule now align with the actual option grant terms.

What currency is used for Marina Bozilenko’s Ascentage Pharma (AAPG) option exercise price?

The stock option exercise price is set in Hong Kong dollars, but the table shows a converted figure in U.S. dollars. The footnote explains the 8.1400 value reflects the HKD price translated using the exchange rate on the original grant date.

Do Marina Bozilenko’s Ascentage Pharma (AAPG) restricted share units require an exercise price?

No exercise price applies to her restricted share units, as indicated by a conversion price of 0.0000. Each RSU represents a contingent right to receive one Ordinary Share of Ascentage Pharma once the applicable vesting date is reached and vesting conditions are satisfied.